CIT Group ( CIT ) reported fourth quarter net income of $3.2 billion. Excluding items, CIT reported a fourth quarter pre tax loss of $1 billion. CIT said that it had common equity of $8.4 billion, or $41.99 a share, as of Dec. 31. 
Share:  <span class="company">CIT</span> Group ( <span class="company">CIT</span> ) reported fourth quarter net income of $3.2 billion. Excluding items, <span class="company">CIT</span> reported a fourth quarter pre tax loss of $1 billion. <span class="company">CIT</span> said that it had common equity of $8.4 billion, or $41.99 a share, as of Dec. 31. Tweet this 

Now the big daddy of private equity, Kohlberg Kravis and Roberts. KKR. is finally tapping the New York Stock Exchange for an initial public offering, and that can only mean that the rest of us better hold onto our wallets. 
Share:  Now the big daddy of private equity, <span class="company">Kohlberg Kravis</span> and Roberts. KKR. is finally tapping the New York Stock Exchange for an initial public offering, and that can only mean that the rest of us better hold onto our wallets. Tweet this 

Less than a week after that, AstraZeneca ( ) said that its experimental oncology drug Recentin failed to show any better results than Roche's ( ) Avastin as a treatment for colon cancer in a late stage, head to head trial. That day, Roche and Biogen Idec ( ) announced that they were suspending the development of Ocrelizumab for the treatment of rheumatoid arthritis following serious adverse events in studies of the drug, including deaths of patients. That brings us to this week: On Thursday, Pfizer said two Phase 3 trials of Sutent as a treatment for advanced breast cancer did not meet their primary endpoints. 
Share:  Less than a week after that, AstraZeneca ( ) said that its experimental oncology drug Recentin failed to show any better results than <span class="company">Roche</span>'s ( ) Avastin as a treatment for colon cancer in a late stage, head to head trial. That day, <span class="company">Roche</span> and Biogen Idec ( ) announced that they were suspending the development of Ocrelizumab for the treatment of rheumatoid arthritis following serious adverse events in studies of the drug, including deaths of patients. That brings us to this week: On Thursday, Pfizer said two Phase 3 trials of Sutent as a treatment for advanced breast cancer did not meet their primary endpoints. Tweet this 

After Terra Industries's ( ) board chose to favor a higher bid from CF Industries ( ) of $4.7 billion. Norwegian Yara International said Friday it would not increase its offer to acquire its U. S competitor for $4.1 billion. If Terra chooses the new bid from CF, Terra will owe Yara a $123 million break up fee, according to Yara. 
Share:  After Terra Industries's ( ) board chose to favor a higher bid from <span class="company">CF</span> Industries ( ) of $4.7 billion. Norwegian Yara International said Friday it would not increase its offer to acquire its U. S competitor for $4.1 billion. If Terra chooses the new bid from <span class="company">CF</span>, Terra will owe Yara a $123 million break up fee, according to Yara. Tweet this 

Citigroup Inc ( Chief Executive Vikram Pandit is promising Champagne dreams to shareholders who have gotten used to a light beer reality. In an interview with the Financial Times,. Pandit proclaimed yet again that the company built by Sandy Weill and Chuck Prince is dead. 
Share:  <span class="company">Citigroup</span> Inc ( Chief Executive Vikram Pandit is promising Champagne dreams to shareholders who have gotten used to a light beer reality. In an interview with the Financial Times,. Pandit proclaimed yet again that the company built by Sandy Weill and Chuck Prince is dead. Tweet this 

Last week, Citigroup Inc ( ) Chief Executive Vikram Pandit said the investment bank owed U. S taxpayers a "large debt of gratitude" for providing $45 billion in assistance to the company at the height of the financial crisis, aid which prevented the bank from winding up on the scrap heap of financial history along with Lehman Brothers and Merrill Lynch. Two reports out Wednesday show how Pandit plans to bolster Citigroup's balance sheet after repaying the government for that financial lifeline. Bloomberg News says that the New York based bank will be selling as much as $2 billion of trust preferred securities, known as TruPS, as soon as today. 
Share:  Last week, <span class="company">Citigroup</span> Inc ( ) Chief Executive Vikram Pandit said the investment bank owed U. S taxpayers a "large debt of gratitude" for providing $45 billion in assistance to the company at the height of the financial crisis, aid which prevented the bank from winding up on the scrap heap of financial history along with Lehman Brothers and Merrill Lynch. Two reports out Wednesday show how Pandit plans to bolster <span class="company">Citigroup</span>'s balance sheet after repaying the government for that financial lifeline. Bloomberg News says that the New York based bank will be selling as much as $2 billion of trust preferred securities, known as TruPS, as soon as today. Tweet this